Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alex Williams

Gastroenterology Norfolk, VA Medical Doctor

NPI 1548269483 CMS profile 341866

400 Gresham Dr, Suite 303, Norfolk, VA 23507

Open in the dashboard

General payments

$8,905

458 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alex Williams of Norfolk, VA is reported in the CMS Open Payments database as having received $8,905 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,492 58
2024 General $1,319 60
2023 General $1,284 65
2022 General $1,759 94
2021 General $1,323 81
2020 General $666 39
2019 General $1,061 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alex Williams
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Alex Williams were reported at $1,492. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Alex Williams Gastroenterology median Middle half National median
2019 $1,061 $417 $126–$1,100 $163
2020 $666 $224 $74–$624 $114
2021 $1,323 $352 $106–$1,054 $132
2022 $1,759 $448 $129–$1,270 $149
2023 $1,284 $533 $150–$1,390 $160
2024 $1,319 $605 $160–$1,606 $164
2025 $1,492 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,454 125 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,248 69 payments
  3. Janssen Biotech, Inc. $905 52 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $777 52 payments
  5. Daiichi Sankyo Inc. $557 26 payments
  6. Celgene Corporation $318 23 payments
  7. Regeneron Healthcare Solutions, Inc. $285 12 payments
  8. Ardelyx, Inc. $170 8 payments
  9. Madrigal Pharmaceuticals $170 6 payments
  10. Pfizer Inc. $158 10 payments
  11. Other $1,863 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,888 457 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. ENTYVIO $1,037 52 payments
  2. RINVOQ $1,008 49 payments
  3. STELARA $930 49 payments
  4. HUMIRA $917 51 payments
  5. SIMPONI $603 35 payments
  6. XIFAXAN $571 35 payments
  7. SIMPONI ARIA $525 30 payments
  8. REMICADE $480 28 payments
  9. SKYRIZI $453 21 payments
  10. INJECTAFER $373 16 payments
  11. Other $4,442 235 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

827

Median for Gastroenterology: 569

Drug cost

$48,048

Median for Gastroenterology: $104,976

Branded share of claims

30.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 27 $24,355
Budesonide Ec Budesonide Brand 13 $7,682
Famotidine Generic 212 $3,875
Pantoprazole Sodium Generic 163 $2,301
Sucralfate Generic 15 $2,096
Lubiprostone Generic 12 $2,039
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 91 $1,767
Dicyclomine Hcl Generic 65 $926
Omeprazole Generic 80 $796
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 52 $736

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$155,837

Medicare's payments for the services billed

Medicare patients

537

Average age 72

Services billed

1,075

304 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 38%
Ischemic heart disease 27%
Chronic kidney disease 23%
Atrial fibrillation 19%
COPD 19%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $241
$241 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $187
$187 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $121
$121 — —
RINVOQ
  • AbbVie, Inc. $119
$119 — —
INJECTAFER
  • Daiichi Sankyo Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record